October 2012 Newsletter

October 25, 2012:

Chicago AAO Meeting Promises Information Overload

More than 30,000 people are expected to attend this year’s AAO meeting in Chicago. Market Scope highlights the top agenda items.

Laser Refractive Surgery
Corneal Inlays
Corneal Crosslinking
Diagnostic Equipment/Photocoagulation Lasers
Presbyopia Correcting IOLs
Toric IOLs
Phakic IOLs
Femtosecond Laser-assisted Cataract Surgery
Phaco Techniques and Technology
ATGS Devices
Vitreoretinal Programs
Dry AMD
Inherited Retinopathies
VMA
Wet AMD
Diabetic Eye Disease

October 25, 2012:

FDA Advisory Panel Recommends Approval for Second Sight Implant for Retinitis Pigmentosa

An FDA advisory panel has recommended approval of Second Sight’s request for an HDE (Humanitarian Device Exemption) for its Argus II retinal implant for retinitis pigmentosa.

October 25, 2012:

UK Health Officials Reverse Ruling on Lucentis for Treatment of DME, Wet AMD

Cutting the price of Lucentis in the UK appears to be paying off for Novartis, which holds the rights to sell the anti-VEGF drug outside the US.

October 25, 2012:

Retinal Pharmaceuticals Market Forecast to Climb at Rate of 12.5 Percent through 2017

The market in retinal pharmaceuticals and biologics has experienced dramatic growth, evolving into one of the largest segments in the ophthalmic industry today.

October 25, 2012:

FDA Approves Jetrea

Thrombogenics' new enzymatic vitreolytic will be the first drug to enter the market for vitreomacular adhesion, a condition that can occur following posterior vitreous detachment.

October 25, 2012:

Billions of Dollars at Stake in Compounding Scandal

The ophthalmic pharmaceutical market may be on the verge of a dramatic shift due to fallout from the latest compounding scandal.

October 25, 2012:

October 2012 News Briefs

Social media